CoChat

Antidepressant Use Prospectively Relates to a Poorer Long-Term Outcome of Depression: Results from a Prospective Community Cohort Study over 30 Years

Open access
Hengartner, Michael P., Angst, Jules, Rössler, Wulf · 2018 · Psychotherapy and Psychosomatics
Cited by 42

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

4,547 19/20-year-olds from Zurich, Switzerland, randomly drawn in 1978 from the respective age cohort. Of these, a stratified sample of n = 591 participants composed of two thirds with increased psychopathological distress was selected for a comprehensive longitudinal study [9]. Repeated assessments of this cohort with a semistructured personal interview conducted by trained psychologists and psychiatrists took place in 1979 at the age of 20/21 years (n = 591), 1981 at 22/23 (n = 456), 1986 at 27/28 (n = 457), 1988 at 29/30 (n = 424), 1993 at 34/35 (n = 407), 1999 at 40/41 (n = 367), and 2008 at the age of 49/50 years (n = 335). For detailed information, see the online supplementary material (for all online suppl. material, see www.karger.com/doi/10.1159/000488802). The primary outcome was depression within the past 12 months graded according to severity. Major depression based on DSM-IV criteria was defined as the severest form (coded as 3). Subthreshold depression was defined by 3–4 of 9 criterial symptoms with a minimum duration of 2 weeks or by 5 or more symptoms lasting less than 2 weeks (coded as 2). All other forms were defined as depression symptoms (coded as 1). Depression was considered absent if no symptoms were reported (coded as 0). The predictor variable was self-reported prescription of antidepressant drugs within the past 12 months. To minimise the effect of confounding by indication we adjusted for sociodemographics, family history of depression, severe depression at baseline, severe suicidality at baseline, and any affective disorder at baseline. Severe depression was defined as meeting criteria for major depression and reporting a distress of 70 or more on a visual analogue scale ranging from 0 to 100, whereas 12-month prevalence of severe suicidality was defined as present when participants endorsed 1 of the following 3 items: (1) “I had serious persisting thoughts of harming myself”; (2) “I had clear and precise ideas of how to commit suicide”; (3) “I made a suicide attempt.” All associations were estimated with time-lagged generalised estimating equations. We used antidepressant use at time point t as a predictor of subsequent depression severity at time point t + 1 (i.e., antidepressants at the age of 20/21 related to depression at 22/23 years, antidepressants at 22/23 years related to depression at 27/28 years, and so on). Across the entire 30-year observation period, the rate of antidepressant use was 6% in persons with depression symptoms, 7% in persons with subthreshold depression, and 22% in persons with major depression (more information is provided in the online suppl. material). The prospective association between antidepressant use and subsequent depression severity is shown in Table 1. The effect was statistically highly significant (all p < 0.01) and substantial in magnitude (range odds ratio: 1.7–1.8 for 1-point increase in depression severity) in all 4 models. In the first model we report the unadjusted bivariate association and in the second model we adjust for sociodemographics. In the third model we additionally adjust for severe depression at baseline and for family history of depression. To further minimise confounding by indication, in the fourth model we control for baseline affective disorder and severe suicidality. Adding further covariates, such as subjective depresDespite marked increases in antidepressant drug prescriptions over the last 3 decades, the burden and disability attributed to major depression are still on the rise. This calls into question the sustainable clinical benefits attributed to antidepressants. The efficacy of antidepressants based on mostly industry-funded short-term trials has been challenged due to selective reporting and systematic method biases (e.g., unblinding of outcome assessors), and the long-term benefits of antidepressants have also been debated [1, 2]. Two long-term effectiveness trials of 1 year duration found no clinically important effect in terms of sustained remission for longterm antidepressant use (the sustained remission rate was < 6% [3, 4]), and a meta-analysis of long-term parallel-arm efficacy trials of 6–8 months treatment duration found no significant difference between antidepressants and placebo with respect to both remission and premature treatment discontinuation [5]. Some prospective observational studies with 1to 9-year follow-ups even reported a poorer outcome in antidepressant users relative to non-users [6–8]. In contrast to these findings, discontinuation trials of commonly 6–18 months duration suggest that long-term antidepressant use may prevent relapses (reviewed in Hengartner [1]). However, the validity of these trials has been questioned, because they include only participants who respond well to the drugs and randomise some of them to have the drug withdrawn rapidly and replaced by placebo, which can cause severe withdrawal syndromes that mimic depression relapse [1, 2]. Since extended observation periods of 10 years and more are not feasible within a randomised placebo-controlled trial design, the aim of the present work was to test in a representative community cohort study over 30 years whether antidepressant use, relative to non-use, would relate to a poorer long-term outcome of depression. For it we analysed data from the longitudinal Zurich Cohort Study, which is based on a representative screening sample of n = Received: January 18, 2018 Accepted after revision: March 26, 2018 Published online: April 20, 2018

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000488802

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 42

Metadata

Authors
Hengartner, M. P., Angst, J., & Rössler, W.
Venue
Psychotherapy and Psychosomatics
Publisher
S. Karger AG
Published
2018
Volume
87
Issue
3
Pages
181-183
ISSN
  • 0033-3190 (ISSN-L)
  • 1423-0348
OpenAlex
W2799853313
Cited by
42
References
4
FWCI
3.38
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.